CoChat

Postprandial Insulin Lispro: A new therapeutic option for type 1 diabetic patients

Schernthaner, Guntram, Wein, Wolfgang, Sandholzer, Klaudia, Equiluz-Bruck, Susanna, Bates, Peter C, Birkett, Martin A · 1998 · Diabetes Care
Cited by 74

The DOI matches its Crossref record.

Abstract

OBJECTIVE: For intensified insulin therapy of type 1 diabetes, bolus injection of regular human insulin 30–15 min before a meal is currently recommended. This randomized study is aimed to determine whether insulin lispro (LIS), a new insulin analog with a rapid onset of action, can provide comparable blood glucose (BG) control by injection after the meal. RESEARCH DESIGN AND METHODS: Eighteen type 1 diabetic subjects injected regular insulin (REG) at 40, 20, or 0 min before or LIS at 20 or 0 min before or 15 min after the start of a standardized test meal. BG excursions and area under the curve of BG excursions (AUC) at the six visits were compared by analysis of variance. Hypoglycemic events (BG ≤2.78 mmol/1) were evaluated in relation to the achieved postprandial BG control. RESULTS: Mean AUC values were 2.00, 2.55, and 3.33 mmol · h · 1−1 for REG given 40, 20, and 0 min before the test meal, respectively, and −2.19, −2.15, and 1.98 mmol · h · 1−1 for LIS given 20 and 0 min before and 15 min after the start of the test meal, respectively. LIS injected 20 min (−20) or immediately (0) before the meal was significantly more effective in controlling postprandial BG excursion (P < 0.001) than any REG treatment. Postprandial injection of LIS (15) did not compromise postprandial BG control and resulted in less hypoglycemia. REG −40 and LIS −20 were associated with early hypoglycemia, but other hypoglycemic events were equally distributed among groups. CONCLUSIONS: The optimal time for bolus insulin injection was 20 min before the meal for REG and immediately before the meal for LIS. LIS injected immediately after a standard meal provided postprandial BG control at least as good as REG injected from 40 to 0 min before the meal. Postprandial injection of LIS is an attractive new therapeutic option.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/diacare.21.4.570

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 74

Metadata

Authors
Schernthaner, G., Wein, W., Sandholzer, K., Equiluz-Bruck, S., Bates, P. C., & Birkett, M. A.
Venue
Diabetes Care
Published
1998-04-01
Volume
21
Issue
4
Pages
570-573
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2063759865
Cited by
74
References
0
FWCI
4.42
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Postprandial Insulin Lispro: A new therapeutic option for type 1 diabetic patients. https://app.cochat.ai/papers/10.2337/diacare.21.4.570
The paper
Schernthaner, G., Wein, W., Sandholzer, K., Equiluz-Bruck, S., Bates, P. C., & Birkett, M. A. (1998). Postprandial Insulin Lispro: A new therapeutic option for type 1 diabetic patients. Diabetes Care. https://doi.org/10.2337/diacare.21.4.570

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.